Hosted on MSN4h
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In 2022, the drug became the first therapy approved for H
The FDA pulls key DEI initiative for cancer studies from its website
A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the agency's website, as the Trump administration halts DEI initiatives.
CNET2d
FDA Finally Bans Red Dye No. 3: What You Need to Know
The US Food and Drug Administration announced this month that it's effectively banning Red No. 3, the controversial artificial red dye found in food and drinks that's been linked to cancer. The decision comes 30 years after scientists first discovered links between the dye and thyroid cancer in animals.
Healio1d
FDA expands Enhertu approval for breast cancer
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of the agent by patients with HER2-low or HER2-utralow metastatic breast cancer whose disease progressed after at least one endocrine therapy.
The FDA has officially banned Red No. 3. Here are some products that contain the cancer-causing dye
In a bombshell announcement made last week, the Food and Drug Administration (FDA) said it will ban the use of FD&C Red No. 3, a synthetic food dye, from the nation’s food supply. The latest initiative comes more than three decades after the colorant was barred from cosmetics and non-oral medications due to potentially causing cancer.
Cure Today2d
FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy.
WebMD7d
FDA Approves New Treatment for Advanced Breast Cancer
The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.
Hosted on MSN3d
Parkinson's disease could be treated by FDA-approved cancer drug after major research breakthrough
A major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the spread of brain proteins believed to be responsible for Parkinson's
Could the FDA's recently approved Pap smear alternative reduce racial disparities in cervical cancer deaths?
Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical cancer.
Targeted Oncology2d
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results.
The American Journal of Managed Care1d
FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.
STAT7d
Pharmalittle: We’re reading about a cancer therapy’s gold rush, FDA warning Sanofi, and more news
A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centered on text messages she exchanged with Pfizer's CEO during negotiations for Covid shots.